The historical rank and industry rank for Structure Therapeutics's Equity-to-Asset or its related term are showing as below:
GPCR'
s Equity-to-Asset Range Over the Past 10 Years
Min: -1.18 Med: 0.89 Max: 0.96
Current: 0.94
During the past 4 years, the highest Equity to Asset Ratio of Structure Therapeutics was 0.96. The lowest was -1.18. And the median was 0.89.
GPCR's Equity-to-Asset is ranked better than 93.2% of 1559
companies
in the Biotechnology industry
Industry Median: 0.67
vs GPCR: 0.94
Structure Therapeutics Equity-to-Asset Historical Data
The historical data trend for Structure Therapeutics's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Structure Therapeutics's Equity-to-Asset
For the Biotechnology subindustry, Structure Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Structure Therapeutics's Equity-to-Asset Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Structure Therapeutics's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Structure Therapeutics's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Structure Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Structure Therapeutics Equity-to-Asset Related Terms
Thank you for viewing the detailed overview of Structure Therapeutics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Structure Therapeutics (Structure Therapeutics) Business Description
Structure Therapeutics Inc is a clinical-stage global biopharmaceutical company aiming to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small-molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073 and LTSE-2578.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GPCR has been successfully added to your 